hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway

Shen, Jing; Cai, Wenpeng; Ma, Yongfang; Xu, Rui; Huo, Zhen; Wang, Jintao; Qiu, Xinyin; Zhang, Yinci; Li, Amin; Cao, Weiya; Zhou, Shuping; Tang, Xi-can

doi:10.1186/s11671-020-03451-5

Cited by 13 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These carriers enhance drug solubility and stability, thereby improving its efficacy and reducing the adverse side effects that often accompany conventional treatments. For instance, anti-glypican-3, with its significant overexpression in HCC cells, serves as a prime target for sorafenib-loaded polymer nanoparticles[ 8 , 9 ]. GalNAc coupling to asialoglycoprotein, a receptor abundantly expressed on hepatocytes, also emerges as a promising strategy, overcoming hurdles associated with drug resistance and improving the efficiency of liver-specific drug delivery[ 10 , 11 ].…”

Section: Application Of Nanotherapy In Hccmentioning

confidence: 99%

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Lee,

Yuan

2024

World J Hepatol

View full text Add to dashboard Cite

In this editorial we comment on the review by Zhou et al reviewing the landscape of nanomedicine in the treatment of hepatocellular carcinoma (HCC). We focus on the immense potential of nanotechnology, particularly ligand-receptor mediated nanotherapy, in revolutionizing the treatment landscape of HCC. Despite advancements in multidisciplinary treatment, HCC remains a significant global health challenge. Ligand-mediated nanotherapy offers the opportunity for precise drug delivery to tumor sites, targeting specific receptors overexpressed in HCC cells, thereby enhancing efficacy and minimizing side effects. Overcoming drug resistance and aggressive tumor biology is facilitated by nanomedicine, bypassing traditional hurdles encountered in chemotherapy. Examples include targeting glypican-3, asialoglycoprotein, transferrin receptor or folic acid receptors, capitalizing on their over-expression in tumor cells. The ability for multi-receptor targeting through dual-ligand nanoparticle modification holds the prospect of further enhancement in specificity and efficacy of directed therapy. However, challenges including immune responses, reproducibility in nanoparticle synthesis, and production scalability remain. Future directions involve refining targeting strategies, improving drug release mechanisms, and streamlining production processes to enable personalized and multifunctional nanotherapies. Overall, the integration of nanotherapy in HCC treatment holds immense promise, but continued partnership and effort are needed in offering hope for more effective, precise, and accessible clinical care in the management of HCC.

show abstract

Section: Application Of Nanotherapy In Hccmentioning

confidence: 99%

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Lee,

Yuan

2024

World J Hepatol

View full text Add to dashboard Cite

show abstract

“…An in vivo HepG2 xenograft mouse model revealed significant inhibition of tumor growth in the presence of targeted NPs loaded with sorafenib compared to non-targeted NPs and free sorafenib [ 196 ]. GC33 has been used as targeting agent of PEG- b -PLGA NPs loaded with sorafenib [ 197 ]. In vitro studies revealed that GPC3-targeted NPs without loading were able to inhibit HepG2 proliferation, increasing the proportion of cells at G1 phase.…”

Section: Nanoparticles Composed Of Organic-based Nanomaterialsmentioning

confidence: 99%

“…These NPs were also able to inhibit the transduction of the proliferation signal dependent on Wnt3a to inhibit epithelial mesenchymal transition, thus attenuating cell migration. In the in vivo study on HepG2 and HUH7 tumor-bearing mice, an inhibition of tumor growth once targeted-NPs loaded with sorafenib were administered, an increase in mice survival, and no toxic effects compared to free drug and untargeted NPs were observed [ 197 ].…”

Section: Nanoparticles Composed Of Organic-based Nanomaterialsmentioning

confidence: 99%

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies

Mossenta

Busato

et al. 2022

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second most lethal tumor, with a 5-year survival rate of 18%. Early stage HCC is potentially treatable by therapies with curative intent, whereas chemoembolization/radioembolization and systemic therapies are the only therapeutic options for intermediate or advanced HCC. Drug resistance is a critical obstacle in the treatment of HCC that could be overcome by the use of targeted nanoparticle-based therapies directed towards specific tumor-associated antigens (TAAs) to improve drug delivery. Glypican 3 (GPC3) is a member of the glypican family, heparan sulfate proteoglycans bound to the cell surface via a glycosylphosphatidylinositol anchor. The high levels of GPC3 detected in HCC and the absence or very low levels in normal and non-malignant liver make GPC3 a promising TAA candidate for targeted nanoparticle-based therapies. The use of nanoparticles conjugated with anti-GPC3 agents may improve drug delivery, leading to a reduction in severe side effects caused by chemotherapy and increased drug release at the tumor site. In this review, we describe the main clinical features of HCC and the common treatment approaches. We propose the proteoglycan GPC3 as a useful TAA for targeted therapies. Finally, we describe nanotechnology approaches for anti-GPC3 drug delivery systems based on NPs for HCC treatment.

show abstract

“…The evidence suggests that active targeting of nanomaterials has remarkable advantages in the efficacy of drug delivery. In recent years, with advances in biomarker discovery for liver cancer, many nanomaterials with active targeting ability have improved drug delivery, especially of insoluble drugs, with targeted peptides or antibodies used to confer the active targeting ability and thus improve drug bioavailability and therapeutic effects[ 4 , 5 , 32 ].…”

Section: Efficient Drug Delivery To Improve Treatment Efficacymentioning

confidence: 99%

Engineering nanotheranostic strategies for liver cancer

Cao¹,

Zhu²,

Wu³

et al. 2021

WJGO

View full text Add to dashboard Cite

The incidence and mortality of hepatocellular carcinoma have continued to increase over the last few years, and the medicine-based outlook of patients is poor. Given great ideas from the development of nanotechnology in medicine, especially the advantages in the treatments of liver cancer. Some engineering nanoparticles with active targeting, ligand modification, and passive targeting capacity achieve efficient drug delivery to tumor cells. In addition, the behavior of drug release is also applied to the drug loading nanosystem based on the tumor microenvironment. Considering clinical use of local treatment of liver cancer, in situ drug delivery of nanogels is also fully studied in orthotopic chemotherapy, radiotherapy, and ablation therapy. Furthermore, novel therapies including gene therapy, phototherapy, and immunotherapy are also applied as combined therapy for liver cancer. Engineering nonviral polymers to function as gene delivery vectors with increased efficiency and specificity, and strategies of co-delivery of therapeutic genes and drugs show great therapeutic effect against liver tumors, including drug-resistant tumors. Phototherapy is also applied in surgical procedures, chemotherapy, and immunotherapy. Combination strategies significantly enhance therapeutic effects and decrease side effects. Overall, the application of nanotechnology could bring a revolutionary change to the current treatment of liver cancer.

show abstract

hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway

Cited by 13 publications

References 32 publications

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies

Engineering nanotheranostic strategies for liver cancer

Contact Info

Product

Resources

About